Updated Reviewed

Appendix A: Key to Acronyms

General Terms

Acronym/AbbreviationDefinition
17-BMPbeclomethasone 17-monopropionate
ACAAffordable Care Act
ADAPAIDS Drug Assistance Program
Ag/Abantigen/antibody
Alaluminum
ALTalanine aminotransferase
AMPaverage manufacturer price
ARTantiretroviral therapy
ARTASAnti-Retroviral Treatment and Access to Services
ARVantiretroviral
ASPaverage sales price
ASTaspartate aminotransferase
AUCarea under the curve
AUDalcohol use disorder
AUDIT-CAlcohol Use Disorders Identification Test-Consumption
AVatrioventricular
AWPaverage wholesale price
AYAadolescents and young adults
BMDbone mineral density
BUNblood urea nitrogen
Cacalcium
CaCO3calcium carbonate
CBCcomplete blood count
CCBcalcium channel blockers
CD4CD4 T lymphocyte
CDCCenters for Disease Control and Prevention
CHFcongestive heart failure
CIconfidence interval
capsid inhibitor
CKDchronic kidney disease
Clchloride
Cmaxmaximum plasma concentration
Cminminimum plasma concentration
CMVcytomegalovirus
CNScentral nervous system
COCcombined oral contraceptive
CPI-Uconsumer price index-urban
CPKcreatine phosphokinase
Crcreatinine
CrClcreatinine clearance
CSFcerebrospinal fluid
CVcardiovascular
CVDcardiovascular disease
CYPcytochrome P450
D/Mdual/mixed
DAAdirect-acting antiviral
DHAdihydroartemisinin
DILIdrug-induced liver injury
DMdiabetes mellitus
DMPAdepot medroxyprogesterone acetate
DOTdirectly observed therapy
EBVEpstein-Barr virus
ECGelectrocardiogram
eGFRestimated glomerular filtration rate
ESRDend stage renal disease
FCPfederal price ceiling
FDAU.S. Food and Drug Administration
FDCfixed-dose combination
Feiron
FULfederal upper limit
GAHTgender-affirming hormone therapy
GHBgamma-hydroxybutyrate
GIgastrointestinal
gpglycoprotein
GSGilead Sciences
H2histamine 2
H2RAH2 receptor antagonist
HADHIV-associated dementia
HANDHIV-associated neurocognitive disorder
HAVhepatitis A virus
HbA1C  hemoglobin A1c
HBcAbhepatitis B core antibody
HBeAghepatitis B e antigen
HBsAbhepatitis B surface antibody
HBsAghepatitis B surface antigen
HBVhepatitis B virus
HCChepatocellular carcinoma
HCO3bicarbonate
HCVhepatitis C virus
HDhemodialysis
HDLhigh-density lipoprotein
HHSU.S. Department of Health and Human Services
HIVhuman immunodeficiency virus
HIV RNAHIV viral load
HIV-1human immunodeficiency virus type 1
HIV-2human immunodeficiency virus type 2
HIVMA/IDSAHIV Medicine Association of the Infectious Diseases Society of America
HLAhuman leukocyte antigen
HMG-CoAhydroxy-methylglutaryl-coenzyme A
HRhazard ratio
HRSAHealth Resources and Services Administration
HRThormone replacement therapy
hs-CRPhigh-sensitivity C-reactive protein
HSRhypersensitivity reaction
HTLV-1human T-lymphotropic virus-1 type I
IAS–USAInternational AIDS Society–USA
IC50inhibitory concentration
ILinterleukin
IMintramuscular
INintegrase
INRinternational normalized ratio
INSTIintegrase strand transfer inhibitor
IPTisoniazid preventive therapy 
IRISimmune reconstitution inflammatory syndrome
ISRinjection site reactions
IUDintrauterine device
IVintravenous
Kpotassium
LA-ARTlong-acting ART
LAIlong-acting injectable
LDLlow-density lipoprotein
LGBTQlesbian, gay, bisexual, transgender, or queer
LLODlower limits of detection
LTBIlatent tuberculosis infection
MACMycobacterium avium complex
MATmedication-assisted treatment
MATEmultidrug and toxin extrusion transporter
MDRmultidrug resistant
MDR-TBmultidrug-resistant tuberculosis 
MDMAmethylenedioxymethamphetamine
MDRPMedicaid Drug Rebate Program
METmotivational enhancement therapy
Mgmagnesium
MHCmajor histocompatibility complex
MImotivational interviewing
MImyocardial infarction
MPAmedroxyprogesterone acetate
MRImagnetic resonance imaging
MSMmen who have sex with men
MTRmulti-tablet regimen
N/Anot applicable
Nasodium
NA-ACCORDNorth American AIDS Cohort Collaboration on Research and Design
NIHNational Institutes of Health
NNRTInon-nucleoside reverse transcriptase inhibitor
NRTInucleoside/nucleotide reverse transcriptase inhibitor
NTDneural tube defect
OARACOffice of AIDS Research Advisory Council
OATopioid agonist therapy
OATPorganic anion-transporting polypeptide
OBRoptimized background regimen
OCT2organic cation transporter 2
OH-itraconazoleactive metabolite of itraconazole
OIopportunistic infection
ONDCPOffice of National Drug Control Policy
ORodds ratio
OTPopioid treatment program
OUDopioid use disorder
Pphosphorus
P-gpp-glycoprotein
PAHpulmonary arterial hypertension
PBMpharmacy benefit manager
PCPPneumocystis jirovecii pneumonia
PCRpolymerase chain reaction
PDE5phosphodiesterase type 5
PHQ-2Patient Health Questionnaire-2
PEPpost-exposure prophylaxis
PIprotease inhibitor
PI/ccobicistat-boosted protease inhibitor
PI/rritonavir-boosted protease inhibitor
PKpharmacokinetic
POorally
PPIproton pump inhibitor
PRprotease
PrEPpre-exposure prophylaxis
PTHparathyroid hormone
QTcQT corrected for heart rate
REPCRetention through Enhanced Personal Contact
RNAribonucleic acid
RTreverse transcriptase
RWHAPRyan White HIV/AIDS Program
SAMHSASubstance Abuse and Mental Health Services Administration
SCrserum creatinine
SJSStevens Johnson Syndrome
SMACstate maximum allowable cost
SMRsexual maturity rating
SPTskin patch test
SQsubcutaneous
SSRIselective serotonin reuptake inhibitor
STIsexually transmitted infection
STRsingle-tablet regimen
SUDsubstance use disorder
TasPtreatment as prevention
TBtuberculosis
TCtotal cholesterol
TCAtricyclic antidepressant
TDMtherapeutic drug monitoring
TDRtransmitted drug resistance
TGtriglyceride
The PanelThe Panel on Antiretroviral Guidelines for Adults and Adolescents
THRIVETargeting HIV Retention and Improved Viral load through Engagement
U = UUndetectable = Untransmittable
UGTuridine diphosphate glucuronosyltransferase
UGT1uridine diphosphate glucuronosyltransferase 1 family
UGT1A1uridine diphosphate glucuronosyltransferase 1A1
ULNupper limit of normal
USTSU.S. Transgender Survey
UWUniversity of Washington
VLviral load
VPAvalproic acid
WACwholesale acquisition cost
WBCwhite blood cell
WHOWorld Health Organization
WPATHWorld Professional Association for Transgender Health
XDRextensively drug resistant
XRextended release
Znzinc

Appendix A: Key to Acronyms

General Terms

Acronym/AbbreviationDefinition
17-BMPbeclomethasone 17-monopropionate
ACAAffordable Care Act
ADAPAIDS Drug Assistance Program
Ag/Abantigen/antibody
Alaluminum
ALTalanine aminotransferase
AMPaverage manufacturer price
ARTantiretroviral therapy
ARTASAnti-Retroviral Treatment and Access to Services
ARVantiretroviral
ASPaverage sales price
ASTaspartate aminotransferase
AUCarea under the curve
AUDalcohol use disorder
AUDIT-CAlcohol Use Disorders Identification Test-Consumption
AVatrioventricular
AWPaverage wholesale price
AYAadolescents and young adults
BMDbone mineral density
BUNblood urea nitrogen
Cacalcium
CaCO3calcium carbonate
CBCcomplete blood count
CCBcalcium channel blockers
CD4CD4 T lymphocyte
CDCCenters for Disease Control and Prevention
CHFcongestive heart failure
CIconfidence interval
capsid inhibitor
CKDchronic kidney disease
Clchloride
Cmaxmaximum plasma concentration
Cminminimum plasma concentration
CMVcytomegalovirus
CNScentral nervous system
COCcombined oral contraceptive
CPI-Uconsumer price index-urban
CPKcreatine phosphokinase
Crcreatinine
CrClcreatinine clearance
CSFcerebrospinal fluid
CVcardiovascular
CVDcardiovascular disease
CYPcytochrome P450
D/Mdual/mixed
DAAdirect-acting antiviral
DHAdihydroartemisinin
DILIdrug-induced liver injury
DMdiabetes mellitus
DMPAdepot medroxyprogesterone acetate
DOTdirectly observed therapy
EBVEpstein-Barr virus
ECGelectrocardiogram
eGFRestimated glomerular filtration rate
ESRDend stage renal disease
FCPfederal price ceiling
FDAU.S. Food and Drug Administration
FDCfixed-dose combination
Feiron
FULfederal upper limit
GAHTgender-affirming hormone therapy
GHBgamma-hydroxybutyrate
GIgastrointestinal
gpglycoprotein
GSGilead Sciences
H2histamine 2
H2RAH2 receptor antagonist
HADHIV-associated dementia
HANDHIV-associated neurocognitive disorder
HAVhepatitis A virus
HbA1C  hemoglobin A1c
HBcAbhepatitis B core antibody
HBeAghepatitis B e antigen
HBsAbhepatitis B surface antibody
HBsAghepatitis B surface antigen
HBVhepatitis B virus
HCChepatocellular carcinoma
HCO3bicarbonate
HCVhepatitis C virus
HDhemodialysis
HDLhigh-density lipoprotein
HHSU.S. Department of Health and Human Services
HIVhuman immunodeficiency virus
HIV RNAHIV viral load
HIV-1human immunodeficiency virus type 1
HIV-2human immunodeficiency virus type 2
HIVMA/IDSAHIV Medicine Association of the Infectious Diseases Society of America
HLAhuman leukocyte antigen
HMG-CoAhydroxy-methylglutaryl-coenzyme A
HRhazard ratio
HRSAHealth Resources and Services Administration
HRThormone replacement therapy
hs-CRPhigh-sensitivity C-reactive protein
HSRhypersensitivity reaction
HTLV-1human T-lymphotropic virus-1 type I
IAS–USAInternational AIDS Society–USA
IC50inhibitory concentration
ILinterleukin
IMintramuscular
INintegrase
INRinternational normalized ratio
INSTIintegrase strand transfer inhibitor
IPTisoniazid preventive therapy 
IRISimmune reconstitution inflammatory syndrome
ISRinjection site reactions
IUDintrauterine device
IVintravenous
Kpotassium
LA-ARTlong-acting ART
LAIlong-acting injectable
LDLlow-density lipoprotein
LGBTQlesbian, gay, bisexual, transgender, or queer
LLODlower limits of detection
LTBIlatent tuberculosis infection
MACMycobacterium avium complex
MATmedication-assisted treatment
MATEmultidrug and toxin extrusion transporter
MDRmultidrug resistant
MDR-TBmultidrug-resistant tuberculosis 
MDMAmethylenedioxymethamphetamine
MDRPMedicaid Drug Rebate Program
METmotivational enhancement therapy
Mgmagnesium
MHCmajor histocompatibility complex
MImotivational interviewing
MImyocardial infarction
MPAmedroxyprogesterone acetate
MRImagnetic resonance imaging
MSMmen who have sex with men
MTRmulti-tablet regimen
N/Anot applicable
Nasodium
NA-ACCORDNorth American AIDS Cohort Collaboration on Research and Design
NIHNational Institutes of Health
NNRTInon-nucleoside reverse transcriptase inhibitor
NRTInucleoside/nucleotide reverse transcriptase inhibitor
NTDneural tube defect
OARACOffice of AIDS Research Advisory Council
OATopioid agonist therapy
OATPorganic anion-transporting polypeptide
OBRoptimized background regimen
OCT2organic cation transporter 2
OH-itraconazoleactive metabolite of itraconazole
OIopportunistic infection
ONDCPOffice of National Drug Control Policy
ORodds ratio
OTPopioid treatment program
OUDopioid use disorder
Pphosphorus
P-gpp-glycoprotein
PAHpulmonary arterial hypertension
PBMpharmacy benefit manager
PCPPneumocystis jirovecii pneumonia
PCRpolymerase chain reaction
PDE5phosphodiesterase type 5
PHQ-2Patient Health Questionnaire-2
PEPpost-exposure prophylaxis
PIprotease inhibitor
PI/ccobicistat-boosted protease inhibitor
PI/rritonavir-boosted protease inhibitor
PKpharmacokinetic
POorally
PPIproton pump inhibitor
PRprotease
PrEPpre-exposure prophylaxis
PTHparathyroid hormone
QTcQT corrected for heart rate
REPCRetention through Enhanced Personal Contact
RNAribonucleic acid
RTreverse transcriptase
RWHAPRyan White HIV/AIDS Program
SAMHSASubstance Abuse and Mental Health Services Administration
SCrserum creatinine
SJSStevens Johnson Syndrome
SMACstate maximum allowable cost
SMRsexual maturity rating
SPTskin patch test
SQsubcutaneous
SSRIselective serotonin reuptake inhibitor
STIsexually transmitted infection
STRsingle-tablet regimen
SUDsubstance use disorder
TasPtreatment as prevention
TBtuberculosis
TCtotal cholesterol
TCAtricyclic antidepressant
TDMtherapeutic drug monitoring
TDRtransmitted drug resistance
TGtriglyceride
The PanelThe Panel on Antiretroviral Guidelines for Adults and Adolescents
THRIVETargeting HIV Retention and Improved Viral load through Engagement
U = UUndetectable = Untransmittable
UGTuridine diphosphate glucuronosyltransferase
UGT1uridine diphosphate glucuronosyltransferase 1 family
UGT1A1uridine diphosphate glucuronosyltransferase 1A1
ULNupper limit of normal
USTSU.S. Transgender Survey
UWUniversity of Washington
VLviral load
VPAvalproic acid
WACwholesale acquisition cost
WBCwhite blood cell
WHOWorld Health Organization
WPATHWorld Professional Association for Transgender Health
XDRextensively drug resistant
XRextended release
Znzinc

Download Guidelines